(BKLC) BNY Mellon US Large Cap - Overview
Etf: Large-Cap Stocks, Technology, Healthcare, Financials, Consumer
Dividends
| Dividend Yield | 1.14% |
| Yield on Cost 5y | 1.99% |
| Yield CAGR 5y | 8.82% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.8% |
| Relative Tail Risk | 5.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.61 |
| Alpha | -0.07 |
| Character TTM | |
|---|---|
| Beta | 0.964 |
| Beta Downside | 0.995 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.05% |
| CAGR/Max DD | 1.19 |
Description: BKLC BNY Mellon US Large Cap January 10, 2026
The BNY Mellon US Large Cap Core Equity ETF (BKLC) seeks to track a float-adjusted, market-capitalization weighted index of the 500 largest U.S. companies, holding each constituent in proportion to its index weight. Because the index is concentrated in the largest caps, the fund is classified as “non-diversified” despite covering a broad market segment.
As of the most recent filing (Q4 2024), BKLC reports an expense ratio of 0.07 %, an AUM of roughly $4.2 billion, and an average daily trading volume of about 1.1 million shares, indicating good liquidity. The ETF’s sector tilt leans toward Information Technology (≈27 % of assets) and Health Care (≈14 %), reflecting the current dominance of tech-driven earnings growth. Key macro drivers include U.S. consumer spending trends and the Federal Reserve’s policy stance on interest rates, both of which disproportionately affect large-cap equities that are sensitive to valuation multiples and earnings forecasts.
If you want a deeper, data-rich view of BKLC’s risk-adjusted performance and how it fits into a broader portfolio, a quick look at ValueRay’s analytics can be a useful next step.
What is the price of BKLC shares?
Over the past week, the price has changed by -0.24%, over one month by -0.56%, over three months by +2.88% and over the past year by +14.80%.
Is BKLC a buy, sell or hold?
What are the forecasts/targets for the BKLC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 157 | 18.9% |
BKLC Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 5.16b USD (5.16b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 5.16b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 5.16b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.47% (E(5.16b)/V(5.16b) * Re(9.47%) + (debt-free company))
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)